Table 1. Patient characteristics.
| Characteristics | |
|---|---|
| No. of evaluable patients | 117 |
| Age, years | |
| Median | 62 |
| Range | 33–89 |
| Median overall survival,* months | 45 |
| FIGO stage | |
| 1A | 4 (4) |
| 1C | 1 (1) |
| IIB | 2 (2) |
| IIC | 5 (4) |
| IIIA | 1 (1) |
| IIIB | 3 (3) |
| IIIC | 87 (74) |
| IV | 12 (10) |
| Missing | 1 (1) |
| Histological type | |
| Papillary serous | 91 (78) |
| Clear cell | 6 (5) |
| Endometroid | 4 (3) |
| Mucinous | 4 (3) |
| Others (e.g., transitional, mixed) | 12 (10) |
| Grade | |
| 1 | 8 (7) |
| 2 | 4 (3) |
| 3 | 105 (90) |
| Response to frontline therapy | |
| Complete response | 56 (48) |
| Partial response | 57 (49) |
| Progression | 3 (3) |
| Unknown | 1 (1) |
| Residual tumor | |
| None | 55 (47) |
| Present | 56 (48) |
| Unknown | 6 (5) |
| Status | |
| Alive with no evidence of disease | 26 (22) |
| Alive with disease | 31 (27) |
| Dead of disease | 58 (50) |
| Dead with disease | 1 (1) |
| Dead with unknown disease status | 1 (1) |
| CT antigen expression | |
| NY-ESO-1 | 50 (43) |
| MAGE-A1 | 18 (15) |
| MAGE-A4 | 13 (11) |
Data in parentheses are percentages.
*
C.I. = 33–58 months